- Home
- DSM vs MNPR Comparison
DSM vs MNPR Comparison
Compare DSM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- MNPR
- Stock Information
- Founded
- DSM 1989
- MNPR 2014
- Country
- DSM United States
- MNPR United States
- Employees
- DSM N/A
- MNPR N/A
- Industry
- DSM Investment Managers
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- MNPR Health Care
- Exchange
- DSM Nasdaq
- MNPR Nasdaq
- Market Cap
- DSM 289.7M
- MNPR 250.0M
- IPO Year
- DSM N/A
- MNPR 2019
- Fundamental
- Price
- DSM $5.99
- MNPR $40.25
- Analyst Decision
- DSM
- MNPR Strong Buy
- Analyst Count
- DSM 0
- MNPR 4
- Target Price
- DSM N/A
- MNPR $43.00
- AVG Volume (30 Days)
- DSM 161.7K
- MNPR 70.2K
- Earning Date
- DSM 01-01-0001
- MNPR 03-27-2025
- Dividend Yield
- DSM 3.97%
- MNPR N/A
- EPS Growth
- DSM N/A
- MNPR N/A
- EPS
- DSM N/A
- MNPR N/A
- Revenue
- DSM N/A
- MNPR N/A
- Revenue This Year
- DSM N/A
- MNPR N/A
- Revenue Next Year
- DSM N/A
- MNPR N/A
- P/E Ratio
- DSM N/A
- MNPR N/A
- Revenue Growth
- DSM N/A
- MNPR N/A
- 52 Week Low
- DSM $4.69
- MNPR $1.72
- 52 Week High
- DSM $6.05
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- DSM 61.34
- MNPR 49.34
- Support Level
- DSM $5.85
- MNPR $38.80
- Resistance Level
- DSM $6.05
- MNPR $45.60
- Average True Range (ATR)
- DSM 0.05
- MNPR 5.19
- MACD
- DSM 0.01
- MNPR -1.50
- Stochastic Oscillator
- DSM 72.73
- MNPR 9.37
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.